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Table 1. Patient Characteristics
Patient Diagnosis
Donor
Source Virus
Days of
CMX001
treatment
Neutrophil
Engraftment Dose of CMX001 % Donor Engraftment
1 SCID MUD ADV +11 to +54 +13 4 mg/kg/dose BIW 100
2 MDS with
Monosomy 7
MSD CMV +2 to +39 +11 4 mg/kg/dose BIW for 6 doses then 2 mg/kg/
dose BIW x 4 doses
100
3 Autoimmune
neutropenia
and Hepatitis
MUD CMV +3 to +30 +13 4 mg/kg/dose BIW x 7 doses then 4 mg/kg/dose
QW for 1 dose
0
4 XLP MUD HHV6 -48 to +7 +11 2 mg/kg/dose BIW 100
SCID: Severe Combined Immunodeficiency; MDS: Myelodysplastic Syndrome; XLP: X-Linked Lymphoproliferative Disorder; HHV6: Human Herpes
Virus -6; Neutrophil Engraftment: Day post HSCTANC > 500; BIW: twice a week; QW: weekly.
Poster Session I S317undetectable viral DNA in blood. Patient characteristics are shown
in Table 1.
Results:No hematologic toxicity from CMX001 was observed with
prompt neutrophil engraftment in all patients. The patient with au-
tologous recovery was considered to be at very high risk for graft re-
jection secondary to his diagnosis. No adverse events attributable to
CMX001 were seen with either the 4 mg/kg/dose or 2 mg/kg/dose
twice weekly dosing. Three of four patients had a. 1 log drop in vi-
ral load at the end of 1 week of therapy. VR was seen in 3/4 patients
with amedian time to achieve VR of 2 weeks (range 1-3). The patient
who did not have a VR had a.75% decrease in viral load by the end
of week 1 of treatment that was sustained throughout the 6 weeks of
CMX001 treatment.
Discussion: Though a small number of patients were treated, a fa-
vorable safety profile was observed in these patients with no evidence
of delayed hematologic engraftment attributed to CMX001. Four
patients received doses exceeding those currently being studied.
CMX001 is a promising therapy for potential use prior to engraft-
ment in HSCT recipients. Further investigation to confirm the
safety of CMX001 prior to engraftment in HSCT recipients is war-
ranted.300
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Influenza infections following hematopoietic stem cell transplan-
tation (HSCT) are potentially life threatening.While newer antiviral
medications may reduce influenza morbidity, the ideal preventative
strategy is unknown in post-HSCT patients. Prior studies demon-
strate that a single influenza vaccine is relatively ineffective at induc-
ing influenza specific immunity, especially early after HSCT. We
hypothesized that a second vaccine dose, as is standard of care in vac-
cine na€ıve pediatric patients, might improve vaccine efficacy post-
HSCT. During the 2010 influenza season, we conducted a clinical
trial with patients who were.60 days post HSCT, and randomized
them to receive either 1 (n5 30) or 2 (n5 32) flu vaccines separated
by one month. Blood samples were obtained pre-vaccination, 4
weeks and 8 weeks after the first vaccine for hemagglutination and
IFN-g ELISPOT testing. Of the 62 patients, 45 were.18 yrs, 24 re-
ceived non-myeloablative conditioning and 22 were umbilical cord
blood transplant recipients. Hemagglutination responses to the
2010/2011 vaccine components (H3N2, H1N1 and B/Victoria)
were significantly greater for patients vaccinated$1 year post trans-
plant (p\5 0.005 for all 3 strains) compared to those vaccinated at
earlier time points. Testing of T cell specific responses is ongoing,
but week 8 ELISPOT samples show that 7/15 tested patient samples
had IFN-g vaccine specific responses (defined as.10x increase over
baseline). Interestingly, we observed influenza specific T cell re-
sponses in patients without recognizable antibody responses
(n 5 4/15). Vaccine specific T cell responses were observed in 2/8
patients\1 yr post-HSCT and 5/7 .1 yr post-HSCT. Recipientsof 2 vaccines did not show a significant improvement in hemaggluti-
nation responses. This study shows that in some cases vaccinating
before the recommended 6 months post HSCT may be beneficial
sinceT cell responses can be induced. Analysis is ongoing with hopes
to delineate T cell vaccine response relationships between the two
cohorts and the various stem cell sources.301
PULMONARY FUNCTION (PF) AFTER STEM CELL TRANSPLANT (SCT) IS
SIGNIFICANTLY BETTER IN CHILDREN AND ADOLESCENTS WHO RE-
CEIVE REDUCED TOXICITY CONDITIONING (RTC) VERSUS MYELOABLA-
TIVE CONDITIONING (MAC) AND SIGNIFICANTLY DECREASED IN THOSE
WHO DEVELOP CHRONIC GVHD (CGVHD)
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Background: Deterioration in PF after MAC and SCT has previ-
ously been reported in pediatric recipients (Fanfulla et al., ERJ,
1997). RTC has been associated with decreased systemic complica-
tions following SCT (Satwani/Cairo, BBMT, 2005).
Objectives: To determine in a multivariate analysis the risk factors
associated with PF deterioration in pediatric recipients following
SCT.
Design/Method: All patients who underwent SCT under IRB ap-
proved studies were analyzed for PF by standard methods. Reliable
spirometry results pre-SCT and 1-2 years post-SCT were analyzed
on forty recipients, lung volume on twenty-six patients, and diffusion
capacity on thirty-five patients. Pre and post-SCT results were com-
pared using paired t-test analysis. Univariate sub-group analysis was
carried out using the unpaired t-test on the post-SCT results to de-
termine which variables contribute to PF deterioration. All variables
with a p-value less than 0.2 in univariate analysis were included in
a multivariate regression analysis.
Results:M/F 27/13, median age 13 years (5 to 21), malignant/non-
malignant 26/14, and RTC/MAC 26/14. Forced Vital Capacity
(FVC), Forced Expiratory Volume in 1-second (FEV1), Total
LungCapacity (TLC), andDiffusion Capacity (DLCO) were all sig-
nificantly reduced after transplant (Table 1). FEV1/FVC values were
not significantly different before and after SCT.
Sub-group analysis revealed worse PF in patients who underwent
MAC (FVC 71.36 5.3%, FEV1 72.76 4.8%, TLC 74.96 6.4%) as
compared with those who underwent RTC (FVC 80.4 6 2.6%,
FEV1 83.2 6 3.5%, TLC 90.4 6 4.0%) (p 5 0.045, 0.044, and
0.021 respectively). Additionally, patients with cGVHD had signifi-
cantly reduced FVC (68.1 6 4.3% v 81.1 6 2.9%, p 5 0.009) and
FEV1 (72.26 5.6% v 82.66 3.3%, p5 0.05) when compared to pa-
tients without cGVHD.
In multivariate logistic regression, undergoing RTC vs MAC was
an independent, significant predictor of greater post-SCT TLC
(p5 0.046). Additionally, development of cGVHD was an indepen-
dent, significant predictor for reduced FVC post-transplant
(p 5 0.047).
